EAST BRUNSWICK, N.J.--(BUSINESS WIRE)--Jun 6, 2007 - Savient
Pharmaceuticals, Inc. (NASDAQ: SVNT) announced today that two
abstracts exploring Phase 2 Puricase(R) (PEG-uricase) data and
quality of life in treatment-failure gout patients will be
presented at the European League Against Rheumatism (EULAR) 2007
Annual Congress taking place June 13 - 16th in Barcelona, Spain.
Puricase is a PEGylated recombinant porcine urate oxidase currently
in Phase 3 development for patients with treatment-failure gout.

The abstracts selected for poster presentation on Thursday, June
14 are:

-- "Pharmacokinetics and Pharmacodynamics of PEG-uricase in
Patients with Hyperuricemia and Treatment-Failure Gout" (abstract
#THU0358)

-- "Validation of the SF-36 and HAQ-DI in Patients with
Treatment-Failure Gout" (abstract #THU0359)

The first poster presents pharmacokinetic and pharmacodynamic
data from the 41-patient, 3-month duration, open-label Phase 2
trial of Puricase. The second poster presents an analysis of the
application of instruments for measuring health-related quality of
life and physical functioning to the assessment of patient-reported
outcomes in treatment-failure gout (defined as gout patients for
whom allopurinol is contraindicated or is ineffective).

In addition to the two abstracts accepted for poster
presentation, two additional abstracts have been accepted for
publication on-line. These are:

For information about the EULAR scientific program, please visit
the Congress website at www.eular.org

Savient licensed exclusive, worldwide rights to the technologies
related to Puricase from Duke University ("Duke") of North Carolina
and Mountain View Pharmaceuticals, Inc. ("MVP"), a California
corporatio
n. Duke developed the recombinant porcine uricase enzyme
and MVP developed the PEGylation technology. MVP and Duke were
granted U.S. and foreign patents covering the licensed technology.
Puricase is a registered trademark of Mountain View
Pharmaceuticals, Inc.

ABOUT SAVIENT PHARMACEUTICALS

Savient Pharmaceuticals is a biopharmaceutical company engaged
in developing and marketing pharmaceutical products that target
unmet medical needs in both niche and broader markets. The
Company's lead product development candidate, Puricase(R) for
treatment failure gout, has reported positive Phase 1 and 2
clinical data; patient dosing in Phase 3 clinical studies began in
May 2006 with patient enrollment completed in March 2007. Savient's
experienced management team is committed to advancing its pipeline
and expanding its product portfolio by in-licensing late-stage
compounds and exploring co-promotion and co-development
opportunities that fit the Company's expertise in specialty
pharmaceuticals and biopharmaceuticals with an initial focus in
rheumatology. Savient also manufactures and supplies Oxandrin(R)
(oxandrolone tablets, USP) CIII in the U.S. Further information on
Savient can be accessed by visiting:
http://www.savientpharma.com.

FORWARD-LOOKING LANGUAGE

This news release contains forward-looking statements that are
subject to certain risks, trends and uncertainties that could cause
actual results and achievements to differ materially from those
expressed in such statements. These risks, trends and uncertainties
are in some instances beyond Savient's control. Words such as
"anticipate," "believe," "estimate," "expect," "intend," "plan,"
"will" and other similar expressions help identify forward-looking
statements, although not all forward-looking statements contain
these identifying words. These forward-looking statements involve
substantial risks and uncertainties and are based on current
expectations, assumptions, estimates and projections abo
ut
Savient's business and the biopharmaceutical and specialty
pharmaceutical industries in which Savient operates. Such risks and
uncertainties include, but are not limited to, Savient's stock
price and market conditions, delay or failure in developing
Puricase(R) and other product candidates, difficulties of expanding
Savient's product portfolio through in-licensing, introduction of
generic competition for Oxandrin(R), fluctuations in buying
patterns of wholesalers, potential future returns of Oxandrin or
other products, Savient's continuing to incur substantial net
losses for the foreseeable future, difficulties in obtaining
financing, potential development of alternative technologies or
more effective products by competitors, reliance on third-parties
to manufacture, market and distribute many of Savient's products,
(economic, political and other risks associated with foreign
operations) risks of maintaining protection for Savient's
intellectual property, risks of an adverse determination in ongoing
or future intellectual property litigation, and risks associated
with stringent government regulation of the biopharmaceutical
industry. Savient may not actually achieve the plans, intentions or
expectations disclosed in Savient's forward-looking statements.
Actual results or events could differ materially from the plans,
intentions and expectations disclosed in the forward-looking
statements that Savient makes. Stockholders should not place undue
reliance on the forward-looking statements, which speak only as to
the date of this press release. Savient's forward-looking
statements do not reflect the potential impact of any future
acquisitions, mergers, dispositions, joint ventures or investments
that Savient may make. Except as required by law, Savient does not
assume any obligation to update any forward-looking statements.

(Date:12/8/2016)... 2016 A Small Business Innovative Research (SBIR) ... Health (NIH) to Phoenix -based NeuroEM ... The grant will seek to determine an optimal set ... electromagnetic waves to treat Alzheimer,s Disease. The grant will ... possibly treat other neurologic disorders such as Parkinson,s Disease ...

(Date:12/8/2016)... , ... December 08, 2016 , ... ... of access for customers and employees that are both engaging and easy to ... Service Smart Technology, the software company revealed today its plans to roll out ...

(Date:12/8/2016)... ... December 08, 2016 , ... Catalent Pharma Solutions, the ... and consumer health products, today announced that it had joined the Pharmaceutical Supply ... non-profit organization to unite pharmaceutical and healthcare companies that share a vision of ...

(Date:12/8/2016)... ... December 08, 2016 , ... STAT courier is pleased to announce ... service for Texas, they are expanding their presence in Dallas. One of the most ... will bring new jobs to the Dallas and Forth Worth market. STAT takes pride ...

(Date:12/8/2016)... City, Ga (PRWEB) , ... December 08, 2016 ... ... moving as soon after surgery as possible. With this in mind, SIGVARIS has ... thrombosis (DVT or blood clot) during bed rest and provide the benefits of ...